Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

← catalyst calendar

NCT06740799 · readout in 73 d

Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

12estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-09-30

actual

When the study began enrolling

Primary completion

2026-10-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-10-31

estimated

The whole study's end, after follow-up

First posted

2024-12-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-01

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Hepatic Impairment

Intervention

Drug: Quizartinib — also filed as Test Product, VANFLYTA®